Press Release

Illumina to Announce Second Quarter 2018 Financial Results on Monday, July 30, 2018

SAN DIEGO--(BUSINESS WIRE)--Jul. 10, 2018-- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for second quarter 2018 following the close of market on Monday, July 30, 2018.

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Monday, July 30, 2018. Interested parties may access the live teleconference through the Investor Relations section of Illumina’s web site under the “company” tab at www.illumina.com. Alternatively, individuals can access the call by dialing 800-708-4539, or 1-847-619-6396 outside North America, both with passcode 47172781.

A replay of the conference call will be available from 4:30 pm Pacific Time (7:30 pm Eastern Time) on July 30, 2018 through August 6, 2018 by dialing 888-843-7419, or 1-630-652-3042 outside North America, both with passcode 47172781.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Jacquie Ross, CFA
858-882-2172
ir@illumina.com
or
Media:
Eric Endicott
858-882-6822
pr@illumina.com

Recent Articles

Sustainable sequencing in the new MiSeq i100 Series
Sustainable sequencing in the new MiSeq i100 Series
The growing case for whole-genome sequencing in all blood cancers
The growing case for whole-genome sequencing in all blood cancers
Independent testing proves DRAGEN provides a vastly more comprehensive genome
Independent testing proves DRAGEN provides a vastly more comprehensive genome